Jason Cole
Chief Executive Officer at SalioGen Therapeutics, Inc.
Net worth: 5 644 $ as of 30/05/2024
Jason Cole active positions
Companies | Position | Start | End |
---|---|---|---|
bluebird bio (UK) Ltd.
bluebird bio (UK) Ltd. BiotechnologyHealth Technology Founded in 2016, bluebird bio (UK) Ltd. is a British biotechnology company that engages in research and development. The company is based in Basingstoke, UK and is a subsidiary of bluebird bio, Inc. | Director/Board Member | 13/03/2016 | - |
Corporate Secretary | 13/03/2016 | - | |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Chief Executive Officer | 10/09/2023 | - |
Chairman | 10/09/2023 | - | |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Director/Board Member | - | - |
Career history of Jason Cole
Former positions of Jason Cole
Companies | Position | Start | End |
---|---|---|---|
BLUEBIRD BIO, INC. | Comptroller/Controller/Auditor | 26/04/2022 | 13/10/2022 |
Chief Operating Officer | 10/02/2019 | 03/11/2021 | |
Director of Finance/CFO | 02/04/2022 | 13/10/2022 | |
General Counsel | 28/02/2014 | 03/11/2021 | |
Corporate Officer/Principal | 03/11/2021 | 26/04/2022 | |
Corporate Secretary | 28/02/2014 | 03/11/2021 | |
Treasurer | 02/04/2022 | 13/10/2022 | |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | General Counsel | 13/09/2010 | 04/03/2014 |
Corporate Secretary | 13/09/2010 | 04/03/2014 | |
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | General Counsel | 31/12/2005 | 05/08/2010 |
Corporate Secretary | 31/12/2005 | 05/08/2010 | |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | General Counsel | 27/12/2009 | 26/01/2010 |
Corporate Secretary | 27/12/2009 | 26/01/2010 | |
Ropes & Gray LLP
Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Corporate Officer/Principal | 31/12/2005 | 31/12/2005 |
Training of Jason Cole
Dartmouth College | Undergraduate Degree |
Columbia Law School | Graduate Degree |
Statistics
International
United States | 10 |
United Kingdom | 2 |
Operational
Corporate Secretary | 5 |
General Counsel | 4 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
Private companies | 7 |
---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Neuromed Pharmaceuticals, Inc.
Neuromed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals, Inc. develops new and improved pain medicines. It has multiple programs aimed at addressing this important unmet medical need. Its lead product candidate, ExalgoTM is an extended release formulation of hydromorphone in phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type and T-type calcium channels, an important target directly involved in pain signaling, and includes candidates for potentially treating pain, epilepsy and hypertension. | Health Technology |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
Ropes & Gray LLP
Ropes & Gray LLP Miscellaneous Commercial ServicesCommercial Services Ropes & Gray LLP provides legal and private equity services. Its practice areas include asset management, banking, business and commercial litigation, business restructuring, capital markets and corporate governance and compliance. The company was founded in 1865 and is headquartered in Boston, MA. | Commercial Services |
bluebird bio (UK) Ltd.
bluebird bio (UK) Ltd. BiotechnologyHealth Technology Founded in 2016, bluebird bio (UK) Ltd. is a British biotechnology company that engages in research and development. The company is based in Basingstoke, UK and is a subsidiary of bluebird bio, Inc. | Health Technology |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Health Technology |
Massachusetts Biotechnology Council
Massachusetts Biotechnology Council Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Council is a premier life sciences and healthcare hub with over 1,600 members dedicated to preventing, treating, and curing diseases through transformative science and technology. The non-profit company is based in Cambridge, MA. MassBio works to advance policy and promote education while providing member programs, events, industry information, and services. The company's mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. Founded in 1985 by James P. Sherblom, the CEO is Kendalle Burlin O'Connell. | Commercial Services |
- Stock Market
- Insiders
- Jason Cole
- Experience